LHRH-conjugated Magnetic Iron Oxide Nanoparticles for Detection of Breast Cancer Metastases

SummaryTargeted delivery of superparamagnetic iron oxide nanoparticles (SPIONs) could facilitate their accumulation in metastatic cancer cells in peripheral tissues, lymph nodes and bones and enhance the sensitivity of magnetic resonance imaging (MRI). The specificities of luteinizing hormone releasing hormone (LHRH) and luteinizing hormone/chorionic gonadotropin (LH/CG)- bound SPIONs were tested in human breast cancer cells in vitro and were found to be dependent on the receptor expression of the target cells, the time of incubation and showed saturation kinetics. In incubations with MDA-MB-435S.luc cells, the highest iron accumulation was 452.6 pg Fe/cell with LHRH-SPIONs, 203.6 pg Fe/cell with β-CG-SPIONs and 51.3 pg Fe/cell with SPIONs. Incubations at 4 °C resulted in 1.1 pg Fe/cell. Co-incubation with the same ligands (βCG or LHRH) decreased the iron accumulation in each case. LHRH-SPIONs were poorly incorporated by macrophages. Tumors and metastatic cells from breast cancer xenografts were targeted in vivo in a nude mouse model. LHRH-SPION specifically accumulated in cells of human breast cancer xenografts. The amount of LHRH-SPION in the lungs was directly dependent on the number of metastatic cells and amounted to 77.8 pg Fe/metastastic cell. In contrast, unconjugated SPIONs accumulated in the liver, showed poor affinity to the tumor, and were not detectable in metastatic lesions in the lungs. LHRH-SPION accumulated in the cytosolic compartment of the target cells and formed clusters. LHRH-SPIONs did not accumulate in livers of normal mice. In conclusion, LHRH conjugated SPIONs may serve as a contrast agent for MR imaging in vivo and increase the sensitivity for the detection of metastases and disseminated cells in lymph nodes, bones and peripheral organs.

[1]  Rong Zhou,et al.  Iron oxide nanoparticles as magnetic resonance contrast agent for tumor imaging via folate receptor-targeted delivery. , 2004, Academic radiology.

[2]  Lars Holmgren,et al.  Angiostatin: A novel angiogenesis inhibitor that mediates the suppression of metastases by a lewis lung carcinoma , 1994, Cell.

[3]  Dar-Bin Shieh,et al.  Aqueous dispersions of magnetite nanoparticles with NH3+ surfaces for magnetic manipulations of biomolecules and MRI contrast agents. , 2005, Biomaterials.

[4]  R. Lockey,et al.  Cationic silica nanoparticles as gene carriers: synthesis, characterization and transfection efficiency in vitro and in vivo. , 2004, Journal of nanoscience and nanotechnology.

[5]  R. Perdrisot,et al.  Liver-directed superparamagnetic iron oxide: quantitation of T2 relaxation effects. , 1993, Magnetic resonance imaging.

[6]  S. Braun,et al.  Comparative analysis of micrometastasis to the bone marrow and lymph nodes of node-negative breast cancer patients receiving no adjuvant therapy. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  R. Campbell,et al.  Co-evolution of ligand-receptor pairs , 1994, Nature.

[8]  H Sommer,et al.  Lack of effect of adjuvant chemotherapy on the elimination of single dormant tumor cells in bone marrow of high-risk breast cancer patients. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  R Weissleder,et al.  Improvement of MRI probes to allow efficient detection of gene expression. , 2000, Bioconjugate chemistry.

[10]  C. Rao,et al.  Presence of functional luteinizing hormone/chorionic gonadotropin (hCG) receptors in human breast cell lines: implications supporting the premise that hCG protects women against breast cancer. , 1997, Biology of reproduction.

[11]  N. Rubio,et al.  Metastatic burden in nude mice organs measured using prostate tumor PC‐3 cells expressing the luciferase gene as a quantifiable tumor cell marker , 2000, The Prostate.

[12]  E. Grabbe,et al.  MRI of the breast in patients with metastatic disease of unknown primary , 1999, European Radiology.

[13]  Ellen Warner,et al.  Surveillance of BRCA1 and BRCA2 mutation carriers with magnetic resonance imaging, ultrasound, mammography, and clinical breast examination , 2004, JAMA.

[14]  P. Roche,et al.  A receptor binding site identified in the region 81–95 of the β-subunit of human luteinizing hormone (LH) and chorionic gonadotropin (hCG) , 1993, Molecular and Cellular Endocrinology.

[15]  D. Fischer,et al.  Surface-modified biodegradable albumin nano- and microspheres. II: effect of surface charges on in vitro phagocytosis and biodistribution in rats. , 1998, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[16]  R Weissleder,et al.  Tumoral distribution of long-circulating dextran-coated iron oxide nanoparticles in a rodent model. , 2000, Radiology.

[17]  B. Maldague,et al.  Ferumoxides‐enhanced quantitative magnetic resonance imaging of the normal and abnormal bone marrow: Preliminary assessment , 1999, Journal of magnetic resonance imaging : JMRI.

[18]  I. Fidler,et al.  Influence of organ environment on the growth, selection, and metastasis of human colon carcinoma cells in nude mice. , 1988, Cancer research.

[19]  Matthew J Dalby,et al.  The influence of transferrin stabilised magnetic nanoparticles on human dermal fibroblasts in culture. , 2004, International journal of pharmaceutics.

[20]  T. Dimpfl,et al.  Cytokeratin-positive cells in the bone marrow and survival of patients with stage I, II, or III breast cancer. , 2000, The New England journal of medicine.

[21]  R. Cote,et al.  Detection and clinical importance of micrometastatic disease. , 1999, Journal of the National Cancer Institute.

[22]  Earl J. Bergey,et al.  DC Magnetic Field Induced Magnetocytolysis of Cancer Cells Targeted by LH-RH Magnetic Nanoparticles in vitro , 2002 .

[23]  Ralph Weissleder,et al.  A multimodal nanoparticle for preoperative magnetic resonance imaging and intraoperative optical brain tumor delineation. , 2003, Cancer research.

[24]  B. Gawrońska,et al.  Membrane Disrupting Lytic Peptide Conjugates Destroy Hormone Dependent and Independent Breast Cancer Cells in vitro and in vivo , 2003, Breast Cancer Research and Treatment.

[25]  R. Weissleder,et al.  Ultrasmall superparamagnetic iron oxide: characterization of a new class of contrast agents for MR imaging. , 1990, Radiology.

[26]  B. Bonnemain,et al.  Superparamagnetic agents in magnetic resonance imaging: physicochemical characteristics and clinical applications. A review. , 1998, Journal of drug targeting.

[27]  R. Weissleder,et al.  Human transferrin receptor gene as a marker gene for MR imaging. , 2001, Radiology.

[28]  À. Sierra,et al.  Metastatic Behavior of Human Breast Carcinomas Overexpressing the Bcl-xL Gene: A Role in Dormancy and Organospecificity , 2001, Laboratory Investigation.

[29]  R Weissleder,et al.  Bone marrow: ultrasmall superparamagnetic iron oxide for MR imaging. , 1991, Radiology.

[30]  C. Leuschner,et al.  Targeted destruction of androgen‐sensitive and ‐insensitive prostate cancer cells and xenografts through luteinizing hormone receptors , 2001, The Prostate.

[31]  I. Lucet,et al.  Development of superparamagnetic nanoparticles for MRI: effect of particle size, charge and surface nature on biodistribution. , 1996, Journal of microencapsulation.

[32]  A. Schally,et al.  Effective treatment of metastatic MDA-MB-435 human estrogen-independent breast carcinomas with a targeted cytotoxic analogue of luteinizing hormone-releasing hormone AN-207. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[33]  R Weissleder,et al.  High-efficiency intracellular magnetic labeling with novel superparamagnetic-Tat peptide conjugates. , 1999, Bioconjugate chemistry.

[34]  Alan P Koretsky,et al.  MRI detection of single particles for cellular imaging. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[35]  R. Perdrisot,et al.  Iron oxide nanoparticles for use as an MRI contrast agent: pharmacokinetics and metabolism. , 1991, Magnetic resonance imaging.

[36]  L. Schwartz,et al.  MR imaging of the breast in patients with occult primary breast carcinoma. , 1997, Radiology.

[37]  T. Reimer,et al.  Simultaneous immunohistochemical detection of tumor cells in lymph nodes and bone marrow aspirates in breast cancer and its correlation with other prognostic factors. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[38]  Shimon Weiss,et al.  Bioactivation and cell targeting of semiconductor CdSe/ZnS nanocrystals with phytochelatin-related peptides. , 2004, Journal of the American Chemical Society.

[39]  Min-Hung Liao,et al.  Direct Binding and Characterization of Lipase onto Magnetic Nanoparticles , 2003, Biotechnology progress.

[40]  J Bittoun,et al.  Cell internalization of anionic maghemite nanoparticles: Quantitative effect on magnetic resonance imaging , 2003, Magnetic resonance in medicine.

[41]  E. Rummeny,et al.  Monitoring radiation‐induced changes in bone marrow histopathology with ultra‐small superparamagnetic iron oxide (USPIO)‐enhanced MRI , 1999, Journal of magnetic resonance imaging : JMRI.

[42]  Alan P Koretsky,et al.  Highly efficient endosomal labeling of progenitor and stem cells with large magnetic particles allows magnetic resonance imaging of single cells. , 2003, Blood.

[43]  N. Kröger,et al.  Disseminated breast cancer cells prior to and after high-dose therapy. , 2001, Journal of hematotherapy & stem cell research.

[44]  R Weissleder,et al.  Normal T-cell response and in vivo magnetic resonance imaging of T cells loaded with HIV transactivator-peptide-derived superparamagnetic nanoparticles. , 2001, Journal of immunological methods.

[45]  Klaus Pantel,et al.  Molecular signature associated with bone marrow micrometastasis in human breast cancer. , 2003, Cancer research.

[46]  Nathan Kohler,et al.  Surface modification of superparamagnetic magnetite nanoparticles and their intracellular uptake. , 2002, Biomaterials.

[47]  K. Offit,et al.  Breast MRI for women with hereditary cancer risk. , 2004, JAMA.

[48]  Dong-Hwang Chen,et al.  Preparation and characterization of YADH-bound magnetic nanoparticles , 2002 .

[49]  M. Neumaier,et al.  Sensitive and specific cytokeratin 18 reverse transcription-polymerase chain reaction that excludes amplification of processed pseudogenes from contaminating genomic DNA. , 1997, Clinical chemistry.

[50]  K. Pantel,et al.  Occult micrometastasis: enrichment, identification and characterization of single disseminated tumour cells. , 2001, Seminars in cancer biology.

[51]  A. Jemal,et al.  Cancer Statistics, 2005 , 2005, CA: a cancer journal for clinicians.

[52]  Ralph Weissleder,et al.  Noninvasive detection of clinically occult lymph-node metastases in prostate cancer. , 2003, The New England journal of medicine.

[53]  C. Hoeller,et al.  MR imaging of the her2/neu and 9.2.27 tumor antigens using immunospecific contrast agents. , 2004, Magnetic resonance imaging.

[54]  C. Leuschner,et al.  Human prostate cancer cells and xenografts are targeted and destroyed through luteinizing hormone releasing hormone receptors , 2003, The Prostate.

[55]  Brian K Rutt,et al.  Imaging single mammalian cells with a 1.5 T clinical MRI scanner , 2003, Magnetic resonance in medicine.

[56]  N. Harbeck,et al.  Detection and clinical implications of early systemic tumor cell dissemination in breast cancer. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[57]  T. Powles,et al.  Increased detection of mammary carcinoma cells in marrow smears using antisera to epithelial membrane antigen. , 1981, British Journal of Cancer.

[58]  C. Kumar,et al.  Efficacy of lytic peptide-bound magnetite nanoparticles in destroying breast cancer cells. , 2004, Journal of nanoscience and nanotechnology.

[59]  Isabelle Raynal,et al.  Macrophage Endocytosis of Superparamagnetic Iron Oxide Nanoparticles: Mechanisms and Comparison of Ferumoxides and Ferumoxtran-10 , 2004, Investigative radiology.

[60]  Carola Leuschner,et al.  Sub-cellular accumulation of magnetic nanoparticles in breast tumors and metastases. , 2006, Biomaterials.

[61]  T J Brady,et al.  Ferrite particles: a superparamagnetic MR contrast agent for the reticuloendothelial system. , 1987, Radiology.

[62]  H. Katabuchi,et al.  Expression of variant luteinizing hormone/chorionic gonadotropin receptors and degradation of chorionic gonadotropin in human chorionic villous macrophages. , 2005, Placenta.

[63]  L. Tiefenauer,et al.  In vivo evaluation of magnetite nanoparticles for use as a tumor contrast agent in MRI. , 1996, Magnetic resonance imaging.

[64]  C. Leuschner,et al.  Minireview. Targeting Breast and Prostate Cancers Through Their Hormone Receptors1 , 2005, Biology of reproduction.

[65]  G. Elizondo,et al.  Liver-specific contrast agents for MRI. , 1990, Investigative radiology.

[66]  R Weissleder,et al.  Superparamagnetic iron oxide: pharmacokinetics and toxicity. , 1989, AJR. American journal of roentgenology.